Möchten Sie immer auf dem neuesten Stand bleiben?

Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is...

New York, March 24, 2026 (GLOBE NEWSWIRE) -- Depression is a fundamentally episodic psychiatric disorder, but the mechanisms that drive mood-state transitions over time are not well understood. We...

From the NFL to the Olympics, athletes face growing mental health challenges; Dianetics offers practical tools for focus and improved performance.

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- It can be a difficult task to support an individual struggling with mental illness when you don’t understand it. Mental health is complicated and...

Guidelight Health Announces New CGO Kelly Jones

Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congressesGH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCash,...

Dianetics volunteers reached tens of thousands worldwide this weekend, offering tools to reduce stress and improve mental well-being

Mental health challenges in professional football highlight the urgent need for practical support and solutions for players.

Former NBA players discuss mental health challenges and how tools like Dianetics help navigate life beyond the game.

FundaMental Pharma chosen among twelve companies to showcase its groundbreaking TRD candidate, FMP374, at the Bio-Neuroscience Conference.